116 related articles for article (PubMed ID: 9167773)
1. Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research.
Pousette A; Carlström K; Henriksson P; Grande M; Stege R
Prostate; 1997 May; 31(3):198-203. PubMed ID: 9167773
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r.
Hansenson M; Lundh B; Hartley-Asp B; Pousette A
Urol Res; 1988; 16(5):357-61. PubMed ID: 3201650
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Serafin AM; Akudugu JM; Bohm L
Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
[TBL] [Abstract][Full Text] [Related]
4. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth.
Motta M; Dondi D; Moretti RM; Montagnani Marelli M; Pimpinelli F; Maggi R; Limonta P
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):107-11. PubMed ID: 8603030
[TBL] [Abstract][Full Text] [Related]
5. Difference in uptake of 3H-estramustine in two human prostatic carcinoma cell lines, LNCaP and LNCaP-r.
Hasenson M
Urol Res; 1989; 17(2):103-6. PubMed ID: 2734976
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.
Zhao X; van Steenbrugge GJ; Schröder FH
Urol Res; 1992; 20(3):193-7. PubMed ID: 1615580
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
10. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
11. The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.
van Steenbrugge GJ; Groen M; van Dongen JW; Bolt J; van der Korput H; Trapman J; Hasenson M; Horoszewicz J
Urol Res; 1989; 17(2):71-7. PubMed ID: 2660395
[TBL] [Abstract][Full Text] [Related]
12. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
Berns EM; de Boer W; Mulder E
Prostate; 1986; 9(3):247-59. PubMed ID: 2946029
[TBL] [Abstract][Full Text] [Related]
13. [Androgen regulation of secreted growth factors in prostate carcinoma cell and tumor lines].
Kellner U; Wagner B; Otto U; Voigt KD; Dietel M; Knabbe C
Verh Dtsch Ges Pathol; 1993; 77():124-8. PubMed ID: 7511269
[TBL] [Abstract][Full Text] [Related]
14. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
15. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells.
Dalkin AC; Gilrain JT; Bradshaw D; Myers CE
Endocrinology; 1996 Dec; 137(12):5230-5. PubMed ID: 8940339
[TBL] [Abstract][Full Text] [Related]
16. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
17. LNCaP-OM, a new androgen-resistant prostate cancer subline.
Platica M; Verma RS; Macera MJ; Platica O
In Vitro Cell Dev Biol Anim; 1997 Mar; 33(3):147-9. PubMed ID: 9112118
[No Abstract] [Full Text] [Related]
18. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
19. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
20. Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line.
Guillemette C; Hum DW; Bélanger A
Endocrinology; 1996 Jul; 137(7):2872-9. PubMed ID: 8770908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
